je.st
news
Tag: diabetes
Johnson & Johnson starts first disease-interception projects, targeting diabetes and lab tests
2015-06-11 16:06:20| Biotech - Topix.net
This undated product image provided by Johnson & Johnson shows Emulate's Organ-On-Chips technology, a computer chip designed to simulate functions of human organs to predict which experimental drugs are most likely to be effective and safe in people. The project is aimed at limiting the failure of drugs after they get into expensive testing in patients.
Tags: projects
tests
johnson
starts
No Heart Safety Issues Seen With Merck Januvia Diabetes Drug: Study
2015-06-09 17:50:34| Biotech - Topix.net
Details of a large heart safety study presented on Monday appear to give Merck and Co's diabetes drug Januvia a clean bill of health, possibly setting the stage for a return to sales growth for the drugmaker's biggest product. Merck in April said the study, called Tecos, of 14,724 patients with type 2 diabetes and a history of heart disease demonstrated that adding Januvia to usual care did not increase major heart problems any more than adding a placebo, removing a cloud that has been holding back sales of the medicine and the company's share price.
Tags: issues
study
heart
safety
TECOS, Mercks Cardiovascular Safety Trial of JANUVIA (sitagliptin), Met Primary Endpoint in Patients with Type 2 Diabetes
2015-06-08 22:30:00| Merck.com - Product News
Dateline City: KENILWORTH, N.J. Findings Published in the New England Journal of Medicine and Presented at the American Diabetes Association Scientific Sessions Treatment with Sitagliptin Did Not Increase the Risk of Major Adverse Cardiovascular Events in the Primary Composite Endpoint, or Hospitalization for Heart Failure, Compared with Placebo KENILWORTH, N.J.--(BUSINESS WIRE)--Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced the primary results of the Trial Evaluating Cardiovascular Outcomes with Sitagliptin (TECOS), a placebo-controlled study of the cardiovascular (CV) safety of Mercks DPP-4 inhibitor, JANUVIA (sitagliptin), added to usual care in more than 14,000 patients. Language: English Contact: MerckMedia:Pam Eisele, 267-305-3558orKim Hamilton, 908-740-1863orInvestors:Joe Romanelli, 908-740-1986orJustin Holko, 908-740-1879 Media Capsule: Please Activate Javascript !function(d, s, id){var js,fjs=d.getElementsByTagName(s)[0],p=/^http:/.test(d.location)?'http':'https',dt=new Date().getTime();if(!d.getElementById(id)){js=d.createElement(s);js.id=id;js.src=p+"://s3.amazonaws.com/contentcapsule.com/clients/Merck/tags/d5542d85-2f26-45dc-b64c-3ee84a4312ff_reg_frame.js?dt="+dt;fjs.parentNode.insertBefore(js,fjs);}}(document,"script","contentcapsule-embed-d5542d85-2f26-45dc-b64c-3ee84a4312ff"); Ticker Slug: Ticker: MRK Exchange: NYSE read more
Takeda warns of loss after $2.4 bn diabetes drug settlements
2015-04-29 09:19:20| Biotech - Topix.net
Top Japanese drugmaker Takeda Pharmaceutical on Wednesday warned of its first annual loss in more than six decades after agreeing to pay around $2.4 billion to settle lawsuits over its Actos diabetes drug, amid cancer claims. The company said costs regarding the US lawsuits would send it into the red for the first time since it was listed on stock exchanges in 1949.
Tags: loss
drug
diabetes
settlements
Tim McGraw, Merck and the American Diabetes Association Challenge Americans with Type 2 Diabetes to Get to Their A1C Goal
2015-04-22 14:00:22| Merck.com - Corporate News
Dateline City: Kenilworth, NJ Platinum-Recording Artist and Actor Rallies People to Make a Pledge with Americas Diabetes Challenge: Get to Your Goals Program KENILWORTH, N.J., April 22, 2015 Merck (NYSE: MRK), known as MSD outside the United States and Canada, and the American Diabetes Association, today announced that award-winning artist Tim McGraw, who has loved ones impacted by type 2 diabetes, will travel the country to urge people with the disease to get their blood glucose under control. Language: English read more
Sites : [1] [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] [18] [19] [20] next »